No Data
No Data
No Data
No Data
No Data
Microba's Revenue Climbs 297% in Fiscal Q3
Microba Life Sciences' (ASX:MAP) revenue surged 297% year-on-year to AU$4 million in the third fiscal quarter as the medical diagnostics company launched its world-first pathogen test, according to a
MT NewswiresApr 24 05:40
Microba Life Sciences Secures AU$6 Million Tax Rebate for Fiscal Year 2023; Shares Fall 5%
Microba Life Sciences (ASX:MAP) secured a AU$6.1 million rebate from the Australian government's research and development tax incentive scheme for the fiscal year ended June 30, 2023, according to a W
MT NewswiresApr 10 09:43
Microba's Domestic Revenues to Get Boost From Sonic Partnership -- Market Talk
2257 GMT - Microba Life Sciences' domestic revenues will be boosted by the roll-out of its gastrointestinal infectious disease test via Sonic Healthcare, Bell Potter analyst Thomas Wakim says. He poin
WSJMar 19 06:57
Australian Shares Track Gains of Wall Street Peers as Market Shrugs Off US Inflation Data
Australian shares on Wednesday tracked the gains of their Wall Street peers, which rallied despite the stronger-than-expected US inflation data. The S&P/ASX 200 Index rose 16.90 points, or 0.2%, to 7,
MT NewswiresMar 13 13:51
Microba Life Sciences Rise 9% Following Launch of MetaPanel Test With Sonic Healthcare
Microba Life Sciences (ASX:MAP) said the MetaPanel product was launched Wednesday to healthcare professionals. The gastrointestinal pathogen test is available exclusively through Sonic Healthcare (ASX
MT NewswiresMar 13 09:30
Miroba Life Sciences Price Target Cut 20% to A$0.35/Share by Bell Potter
Miroba Life Sciences Price Target Cut 20% to A$0.35/Share by Bell Potter
Dow JonesMar 1 05:22
No Data
No Data